New hope for lung cancer relapse: drug combo trial launches
NCT ID NCT06680050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving radiotherapy followed by two drugs—durvalumab (an immunotherapy) and ceralasertib (a targeted therapy)—can help people with stage III non-small cell lung cancer whose cancer has returned in the chest after standard treatment. The study will enroll 21 adults and measure safety, tumor shrinkage, and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) and ceralasertib (a targeted drug)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer that has returned after initial therapy.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The combination of drugs may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
ASST degli Spedali Civili di Brescia
NOT_YET_RECRUITINGBrescia, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Azienda Ospedaliero - Universitaria di Parma
NOT_YET_RECRUITINGParma, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Azienda Ospedaliero Universitaria Careggi
RECRUITINGFlorence, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Azienda ospedaliera di Padova
NOT_YET_RECRUITINGPadova, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IRCCS Ospedale Policlinico San Martino, Genova
RECRUITINGGenova, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Zurich
NOT_YET_RECRUITINGZurich, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital of Geneva
NOT_YET_RECRUITINGGeneva, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••